Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic ...

Three nano-cap healthcare stocks drew massive attention from retail investors on Stocktwits Tuesday, though not all for ...

Danés, principal investigator of the Cancer and Stem Cell Biology Lab at the Champalimaud Foundation, in Lisbon, has shown ...

Dr. Won Jin Ho presented a talk as part of the Immunology Neighborhood Seminar on “Overcoming the tumor immune ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

A study led by Dr. Peter Canoll's lab, in collaboration with researchers at Columbia University Irving Medical Center, ...

Yan et al. recently demonstrated that OGR1 deficiency in host cells may significantly reduce tumor allograft development of prostate cancer cells in the OGR1 knockout mice (Yan et al., 2012). It was ...

Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the way for improved immunotherapies.

In a turbulent period for biotech firms, Evaxion Biotech AS (EVAX) has seen its stock price plummet to $2.38, though InvestingPro analysis suggests the stock may be undervalued. According to ...

A Columbia-led study uncovers how gliomas cause seizures and cognitive impairments by disrupting brain activity. Using ...

For example, since 1976, the National Cancer Institute, USA, has used a drug screening and validation strategy in which human tumour cells are xenotransplanted into immunodeficient mice 2 (Timeline).